NAD supports glucosamine claims

NEW YORK — The National Advertising Division of the Council of Better Business Bureaus on Monday reported Direct Digital, marketer of Instaflex, has supported certain advertising claims made in print and online.

Instaflex is formulated with 1,500 mg glucosamine sulfate, 500 mg methylsulfonylmethane, 250 mg ginger root extract and 4 mg hyaluronic acid. Direct Digital had claimed that Instaflex could relieve and comfort joints and increase flexibility, among other claims.

NAD found that the results of the advertiser's glucosamine studies in support of its claims were in line with the National Institute of Health's "Glucosamine/chondroitin Arthritis Intervention Trial." "At this dosage [1,500 mg], NAD has routinely found a reasonable basis for claims that glucosamine 'lubricates,' 'rebuilds,' 'comforts' and increases 'mobility' of joints," the organization stated.

The review was part of NAD's routine monitoring program through a grant from the CRN Foundation.

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.